Cookson Peirce & Co. Inc. lowered its stake in shares of Genmab A/S (NASDAQ:GMAB) by 23.8% during the 2nd quarter, according to its most recent filing with the SEC. The firm owned 26,820 shares of the company’s stock after selling 8,363 shares during the period. Cookson Peirce & Co. Inc.’s holdings in Genmab A/S were worth $909,000 as of its most recent SEC filing.
Other hedge funds also recently made changes to their positions in the company. UBS Group AG raised its holdings in Genmab A/S by 11.5% in the 4th quarter. UBS Group AG now owns 5,190 shares of the company’s stock worth $116,000 after purchasing an additional 537 shares during the period. Raymond James & Associates boosted its holdings in Genmab A/S by 3.1% in the 1st quarter. Raymond James & Associates now owns 123,514 shares of the company’s stock worth $2,617,000 after buying an additional 3,730 shares during the period. Envestnet Asset Management Inc. increased its stake in Genmab A/S by 15.9% in the 1st quarter. Envestnet Asset Management Inc. now owns 160,049 shares of the company’s stock worth $3,391,000 after buying an additional 21,946 shares in the last quarter. LVW Advisors LLC raised its holdings in Genmab A/S by 35.0% during the first quarter. LVW Advisors LLC now owns 21,369 shares of the company’s stock valued at $453,000 after acquiring an additional 5,543 shares during the period. Finally, Synovus Financial Corp boosted its stake in shares of Genmab A/S by 2.9% in the first quarter. Synovus Financial Corp now owns 98,964 shares of the company’s stock worth $2,096,000 after acquiring an additional 2,743 shares during the period. Hedge funds and other institutional investors own 4.37% of the company’s stock.
GMAB stock traded up $0.75 during midday trading on Thursday, reaching $37.47. 11,638 shares of the company traded hands, compared to its average volume of 689,870. The firm has a market capitalization of $24.19 billion and a price-to-earnings ratio of 15.41. Genmab A/S has a 52-week low of $16.24 and a 52-week high of $38.28. The business has a 50 day moving average of $35.39 and a 200-day moving average of $27.74. The company has a debt-to-equity ratio of 0.02, a quick ratio of 9.53 and a current ratio of 9.53.
A number of research analysts recently commented on GMAB shares. Zacks Investment Research cut Genmab A/S from a “buy” rating to a “hold” rating in a report on Tuesday, July 14th. Societe Generale began coverage on shares of Genmab A/S in a research note on Thursday, July 2nd. They set a “sell” rating for the company. ValuEngine upgraded shares of Genmab A/S from a “strong sell” rating to a “sell” rating in a research note on Monday, August 3rd. HC Wainwright restated a “buy” rating on shares of Genmab A/S in a research report on Thursday, August 13th. Finally, Royal Bank of Canada boosted their target price on Genmab A/S from $35.00 to $38.00 and gave the stock an “outperform” rating in a research report on Thursday, August 13th. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating and eight have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $34.17.
Genmab A/S Profile
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL).
Recommended Story: What is the Shanghai Stock Exchange Composite Index?
Want to see what other hedge funds are holding GMAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Genmab A/S (NASDAQ:GMAB).
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.